Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) is indicated in adults for 'the treatment of symptomatic chronic heart failure'.

2.2 Empagliflozin is recommended for treating heart failure with reduced ejection fraction in adults (NICE technology appraisal guidance 773).

2.3 The dosage schedule is available in the summary of product characteristics for empagliflozin.

2.4 The list price of 10 mg empagliflozin is £36.59 per 28‑tablet pack (excluding VAT; BNF online accessed August 2023). The annual treatment cost is £477.30.